MCAD - Mast Cell Activation Disorder: A Clinical and Patient-Centered Overview
Understanding MCAD: What Is It?
Mast Cell Activation Disorder (MCAD), also referred to as Mast Cell Activation Syndrome (MCAS), is a chronic and often debilitating condition characterized by abnormal and excessive release of chemical mediators from mast cells. These cells are part of the immune system and play a role in allergic responses, but in MCAD, they become hyperactive without appropriate triggers.
This syndrome may be primary (genetic or clonal mast cell disorders), secondary (associated with other conditions), or idiopathic (unknown cause). It frequently overlaps with complex chronic illnesses such as Ehlers-Danlos Syndrome (EDS), dysautonomia, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Dr Gilete achieved the prestigious course “HMX Pro Immunology-Novel Therapies for Chronic Inflammation, Autoimmunity, and Allergy” at the Harvard Medical School (Office of Online Learning, External Education). At our center, Dr Gilete does the differential diagnosis of complex and autoimmune diseases. He coordinates MCAD treatment planning for patients undergoing surgical and nonsurgical protocols at Hospital Teknon.
Recognizing the Symptoms
MCAD presents with a wide range of symptoms, often mimicking other systemic disorders. Common manifestations include:
- Flushing
- Skin rashes or hives
- Anaphylaxis
- Headaches and brain fog
- Abdominal pain, nausea, or diarrhea
- Tachycardia and palpitations
- Fatigue
- Dizziness or syncope
- Temperature sensitivity
- Respiratory symptoms (wheezing, shortness of breath)
The variability and episodic nature of these symptoms complicate the diagnostic process. Many patients are often misdiagnosed or overlooked for years.
Who Is at Risk?
MCAD is commonly seen in individuals with connective tissue disorders, particularly EDS. In our years of specialized practice, we have found that MCAD frequently coexists with neurological conditions such as Craniocervical Instability (CCI), Atlantoaxial Instability (AAI), and Tethered Cord Syndrome.
Dr. Gilete is one of only a very few neurosurgeons in the world experienced in diagnosing CCI and AAI in this neglected patient population. Our interdisciplinary team evaluates each patient holistically, taking into account immune, structural, and genetic factors.
Diagnosing MCAD: From Complexity to Clarity
Historically, diagnosing MCAD relied on elevated tryptase levels during symptomatic episodes or biopsy findings of mast cell infiltration. However, these tests are often invasive and may yield false negatives.
Thanks to recent consensus guidelines, the diagnosis can now be primarily clinical. This means it is based on:
- Thorough clinical history
- Symptom patterns
- Positive response to treatment
- Exclusion of other causes (e.g., mastocytosis, neuroendocrine tumors)
Our diagnostic approach integrates advanced laboratory testing, genetic panels, and inflammation profiling. At Teknon, our imaging and lab teams work in sync to provide reliable results even in complex and overlapping conditions like MCAD + EDS.
Treatment Strategies: Managing the Unpredictable
There is no universal cure for MCAD, but symptoms can be managed with a combination of pharmacological and environmental strategies. Our treatment plans are fully personalized and may include:
- H1 and H2 antihistamines
- Mast cell stabilizers (e.g., cromolyn sodium)
- Leukotriene receptor antagonists
- Low-histamine diets
- Avoidance of known triggers
- Desensitization protocols for medications
- Immunomodulators
In surgical cases involving MCAD patients, we apply our Opioid Free Anesthesia (OFA) protocol, developed by our anesthesiology team to reduce the risk of allergic or mast cell-related reactions. This is especially effective in patients with ME/CFS or multisystem allergies.
Dr Gilete performs complex spinal cord surgeries yearly, many of them involving patients with comorbid MCAD. Our perioperative management includes tailored medication regimens, antimicrobial stewardship, and close collaboration with immunology specialists.
Living With MCAD: Our Clinical Experience
We understand that MCAD often leaves patients feeling isolated or misunderstood. The good news is that a specialized, multidisciplinary team can make a meaningful difference in quality of life. Our director Amy Hyde Smith ensures that every case is handled with personalized care from the initial screening to long-term follow-up.
Whether you opt for an in-person evaluation or teleconsultation, we offer guidance in English, French, Spanish, Swedish or German. Patients traveling to Barcelona for diagnostics or surgery are accompanied throughout every step of the process.
Frequently Asked Questions (FAQs)
What causes MCAD?
MCAD results from inappropriate activation of mast cells, either due to genetic mutations, autoimmune triggers, or idiopathic origins. It can be secondary to infections, trauma, or chronic illness.
Is MCAD the same as mastocytosis?
No. Mastocytosis involves an abnormal increase in the number of mast cells. MCAD involves abnormal activation of a normal number of mast cells.
How is it different from allergies?
Allergies involve specific IgE-mediated immune responses. MCAD involves mediator release and can occur without a clear allergen.
What is the prognosis?
While chronic, many patients see improvements in symptom management through a structured treatment plan and trigger avoidance.
Can it be cured?
Currently, still there is no cure, though important advances have been developed lately, but multidisciplinary care can significantly improve functionality and well-being.
Is MCAD linked to EDS or CCI?
Yes. In our clinical experience, MCAD frequently coexists with Ehlers-Danlos Syndrome and Craniocervical Instability. Treating these together yields better patient outcomes.
Conclusion
MCAD is a multifaceted condition that demands expert evaluation, interdisciplinary care, and individualized treatment strategies. For patients experiencing unexplained systemic symptoms—especially those with EDS or neurological disorders—MCAD should be considered in the differential diagnosis.
Our clinic located at Hospital Teknon in Barcelona combines experience, technology, and compassion to offer care for this neglected condition. With over 25 years of surgical expertise, Dr. Gilete and the Promohealth team are here to help you regain quality of life.
Request your evaluation today
Whether online or in-person, we are ready to assist you. Book your consultation through our contact page and begin your journey toward stability.
Reviewed and approved by Dr. Vicenç Gilete, MD, Neurosurgeon & Spine Surgeon | May 20, 2025